← Leaderboards
Laurence Lemiale
Emergent Product Development Gaithersbur
$61,222,506
Attributed
$61,222,506
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $18.3M · FY2012–23$20M$15M$10M$5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$61,222,506 · 2
By mechanism
N01$61,222,506 · 2
Top collaborators
No co-investigators on record.
Most similar at Emergent Product Development Gaithersbur
Same institution · by research overlap
- Sukjoon Park$31,572,885
- Vijay Yabannavar$4,568,381
- Ajoy Chakrabarti$1,624,359
- Virginia G. Johnson$3,290,712
- Jeffrey Philip Welch$1,553,871
Others in their field
Top investigators on “Advanced Development”
- David Heimbrook · Leidos Biomedical Research, Inc.$625,894,719
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$378,174,673
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$331,630,794
- David H Reitze · University Of Florida$318,606,363
- Albert Lazzarini · California Institute Of Technology$317,303,333
Research focus
Advanced DevelopmentCommunicable DiseasesDisease OutbreaksEventResponseTechnologyVaccinesAnthrax VaccinesCold ChainsCategoriesNational Institute Of Allergy And Infectious DiseaseFormulationSupport ContractsTechnology DevelopmentPathogenBiothreatVaccine DeliveryBiodefenseTranslational ResearchPriority PathogenDrug FormulationsAnthrax DiseaseVaccine DevelopmentDryness
Grant awards (13)
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$476,408
N01 · FY2023 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$69,278
N01 · FY2022 · AI · contact PI
Development of Technologies to Facilitate the Use of and Response to Vaccines$2,739,889
N01 · FY2020 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$3,844,268
N01 · FY2019 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$2,484,726
N01 · FY2018 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$8,677,955
N01 · FY2017 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$4,181,877
N01 · FY2016 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$3,233,217
N01 · FY2015 · AI · contact PI
Development of Technologies to Facilitate the Use of and Response to Vaccines$700,000
N01 · FY2015 · AI · contact PI
Development of Technologies to Facilitate the Use of and Response to Vaccines$10,928,292
N01 · FY2014 · AI · contact PI
DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N$7,386,039
N01 · FY2014 · AI · contact PI
Development of Technologies to Facilitate the Use of and Response to Vaccines$2,045,144
N01 · FY2013 · AI · contact PI
Development of Technologies to Facilitate the Use of and Response to Vaccines$14,455,413
N01 · FY2012 · AI · contact PI